Haemonetics Corporation (NYSE:HAE) Shares Bought by Boston Trust Walden Corp

Boston Trust Walden Corp lifted its holdings in Haemonetics Corporation (NYSE:HAE - Free Report) by 22.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,118,331 shares of the medical instruments supplier's stock after purchasing an additional 202,609 shares during the period. Boston Trust Walden Corp owned about 2.23% of Haemonetics worth $71,070,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in HAE. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth approximately $25,000. Covestor Ltd increased its position in shares of Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after acquiring an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics in the fourth quarter worth approximately $62,000. Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Performance

HAE stock opened at $69.99 on Thursday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62. The stock has a market cap of $3.36 billion, a P/E ratio of 21.15, a P/E/G ratio of 1.12 and a beta of 0.36. The firm has a 50 day simple moving average of $65.79 and a 200 day simple moving average of $68.80. Haemonetics Corporation has a 52 week low of $55.30 and a 52 week high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The firm's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the company posted $0.90 earnings per share. Research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Raymond James Financial reissued a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Needham & Company LLC dropped their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, JMP Securities reissued a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Haemonetics presently has a consensus rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.